Drug Combination Details
| General Information of the Combination (ID: C89761) | |||||
|---|---|---|---|---|---|
| Name | Tetrandrine NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CTNNB1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | WNT5A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | WNT5B | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | OVCAR-3 | CVCL_0465 | Ovarian serous adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo. | |||||
